DLA Piper has advised Kartos Therapeutics. Kartos Therapeutics, a US-based clinical stage biotechnology company, has entered into an agreement to be acquired by the French biopharmaceutical...
Ipsen Acquires Kartos Therapeutics in US$1.75 Billion Deal
RTM Engineering Consultants Receives Strategic Minority Investment from MML Capital
DLA Piper has advised RTM Engineering Consultants. RTM Engineering Consultants, a multidisciplinary engineering consulting firm, has secured a strategic minority investment from international private equity firm...
Red Oak’s Acquisition of 4U Platform
DLA Piper advised 4U Platform on the deal. Red Oak, a leader in advertising compliance and marketing review software, announced its acquisition of 4U Platform, a...
Iovance Biotherapeutics’ $200 Million Acquisition of Proleukin
DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2...
Axsome Therapeutics’ Acquisition of Sunosi
DLA Piper represented Axsome Therapeutics in the transaction. Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced...